JP2021511344A - 癌を治療する組成物および方法 - Google Patents

癌を治療する組成物および方法 Download PDF

Info

Publication number
JP2021511344A
JP2021511344A JP2020540459A JP2020540459A JP2021511344A JP 2021511344 A JP2021511344 A JP 2021511344A JP 2020540459 A JP2020540459 A JP 2020540459A JP 2020540459 A JP2020540459 A JP 2020540459A JP 2021511344 A JP2021511344 A JP 2021511344A
Authority
JP
Japan
Prior art keywords
cancer
compound
antibody
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511344A5 (enExample
Inventor
チーホン・ジャオ
ジョセフ・ファルニョーリ
ムラリ・グルラジャン
スーザン・ウィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021511344A publication Critical patent/JP2021511344A/ja
Publication of JP2021511344A5 publication Critical patent/JP2021511344A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2020540459A 2018-01-22 2019-01-22 癌を治療する組成物および方法 Pending JP2021511344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620209P 2018-01-22 2018-01-22
US62/620,209 2018-01-22
PCT/US2019/014489 WO2019144098A1 (en) 2018-01-22 2019-01-22 Compositions and methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2021511344A true JP2021511344A (ja) 2021-05-06
JP2021511344A5 JP2021511344A5 (enExample) 2022-02-24

Family

ID=65279826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540459A Pending JP2021511344A (ja) 2018-01-22 2019-01-22 癌を治療する組成物および方法

Country Status (13)

Country Link
US (2) US20190224205A1 (enExample)
EP (1) EP3743076A1 (enExample)
JP (1) JP2021511344A (enExample)
KR (1) KR20200112904A (enExample)
CN (1) CN111629731A (enExample)
AU (1) AU2019209435A1 (enExample)
BR (1) BR112020014574A2 (enExample)
CA (1) CA3088542A1 (enExample)
EA (1) EA202091751A1 (enExample)
IL (1) IL276203A (enExample)
MX (1) MX2020007526A (enExample)
SG (1) SG11202006823XA (enExample)
WO (1) WO2019144098A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507444A (ja) * 2009-10-13 2013-03-04 ブリストル−マイヤーズ スクイブ カンパニー Ｎ−（（１Ｒ，２Ｓ，５Ｒ）−５−（ＴＥＲＴ−ブチルアミノ）−２−（（Ｓ）−３−（７−ＴＥＲＴ−ブチルピラゾロ［１，５−ａ］［１，３，５］トリアジン−４−イルアミノ）−２−オキソピロリジン−１−イル）シクロヘキシル）アセトアミド、ケモカイン受容体活性のデュアルモジュレーター、結晶形および製造方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CN102484041B (zh) * 2009-08-21 2015-09-23 第一太阳能有限公司 高温计
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
RU2766890C2 (ru) * 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
EP3389581A2 (en) * 2015-12-15 2018-10-24 The Procter and Gamble Company Leg gasketing cuff with tackifier-free adhesive
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
SMT202200088T1 (it) * 2017-07-20 2022-03-21 Bristol Myers Squibb Co Procedimento per la preparazione di n-((1r,2s,sr)-5-(tert-butilammino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilammino)-2-ossopirrolidin-1-il)cicloesil)acetammide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507444A (ja) * 2009-10-13 2013-03-04 ブリストル−マイヤーズ スクイブ カンパニー Ｎ−（（１Ｒ，２Ｓ，５Ｒ）−５−（ＴＥＲＴ−ブチルアミノ）−２−（（Ｓ）−３−（７−ＴＥＲＴ−ブチルピラゾロ［１，５−ａ］［１，３，５］トリアジン−４−イルアミノ）−２−オキソピロリジン−１−イル）シクロヘキシル）アセトアミド、ケモカイン受容体活性のデュアルモジュレーター、結晶形および製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness", FRONTIERS IN IMMUNOLOGY, vol. 8, JPN6023002331, 2017, ISSN: 0005133026 *

Also Published As

Publication number Publication date
SG11202006823XA (en) 2020-08-28
CN111629731A (zh) 2020-09-04
US20220160718A1 (en) 2022-05-26
US20190224205A1 (en) 2019-07-25
BR112020014574A2 (pt) 2020-12-08
MX2020007526A (es) 2020-09-09
EP3743076A1 (en) 2020-12-02
EA202091751A1 (ru) 2020-11-06
WO2019144098A1 (en) 2019-07-25
KR20200112904A (ko) 2020-10-05
AU2019209435A1 (en) 2020-09-17
IL276203A (en) 2020-09-30
CA3088542A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US20210017285A1 (en) Combination Therapies With Bispecific Anti-EGFR/c-Met Antibodies and Third Generation EGFR Tyrosine Kinase Inhibitors
US20220160718A1 (en) Compositions and methods of treating cancer
CN110869765A (zh) 组合疗法
JP2024508894A (ja) Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
US11596696B2 (en) Combination therapy with an anti-CD25 antibody-drug conjugate
JP2019515916A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
KR20230059792A (ko) 암 치료를 위한 조합
JP2020517629A5 (enExample)
WO2018193103A1 (en) Combination therapy with an anti-psma antibody-drug conjugate
US20200360394A1 (en) Therapies with 3rd generation egfr tyrosine kinase inhibitors
JP2022548627A (ja) 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
JP2025118606A (ja) 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法
CN102458466A (zh) 使用抗-egfr剂和igf-1r特异性的抑制剂的组合治疗
JP7341130B2 (ja) 癌を治療するための組成物および治療方法
CN112638392A (zh) 组合疗法
US20190216923A1 (en) Methods and combination therapy to treat cancer
US20200368205A1 (en) Methods and combination therapy to treat cancer
JP2022533833A (ja) Ｃｄｋ阻害剤を使用した組合せ療法
AU2021320130B2 (en) Treatment of CLL
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
EP4727534A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
WO2024263801A2 (en) Compositions comprising antineoplastons and methods of treating ovarian cancer
EA045355B1 (ru) Комбинированная терапия конъюгатом анти-axl антитело-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230822